NEOMYCIN SULFATE AND DEXAMETHASONE SODIUM PHOSPHATE
Clinical safety rating: safe
Other nephrotoxic or ototoxic drugs increase risk of toxicity Can cause ototoxicity and nephrotoxicity with systemic use.
Neomycin is an aminoglycoside antibiotic that inhibits bacterial protein synthesis by binding to the 30S ribosomal subunit, causing misreading of mRNA and cell death. Dexamethasone is a corticosteroid that suppresses inflammation by inhibiting phospholipase A2, reducing prostaglandin and leukotriene synthesis.
| Metabolism | Neomycin is minimally metabolized; excreted primarily unchanged in urine. Dexamethasone is metabolized in the liver via CYP3A4. |
| Excretion | Renal: neomycin ~30-80% unchanged; dexamethasone phosphate ~80% as free/free glucuronide metabolites. Fecal: negligible. |
| Half-life | Neomycin: 2-3 h (topical/ophthalmic absorption minimal; if significant, prolonged in renal impairment). Dexamethasone: 4-6 h (ophthalmic, systemic if absorbed). |
| Protein binding | Neomycin: minimal to none (~0%). Dexamethasone: ~77% (primarily albumin). |
| Volume of Distribution | Neomycin: 0.2-0.4 L/kg (largely extracellular; limited to local sites). Dexamethasone: 0.6-1.0 L/kg (widely distributed; crosses blood-eye barrier). |
| Bioavailability | Ophthalmic (topical): minimal systemic absorption (<0.1% of dose for both drugs). |
| Onset of Action | Ophthalmic: neomycin/dexamethasone – within 24-48 h for infection/inflammation control; topical (eye drops) – minutes to hours for symptomatic relief. |
| Duration of Action | Ophthalmic: 4-6 h dosing interval typical; duration of clinical effect 6-12 h after single dose. Anti-inflammatory effect lasts 24-48 h after dexamethasone penetration. |
1-2 drops of ophthalmic solution (neomycin 3.5 mg/mL and dexamethasone 1 mg/mL) or ointment (neomycin 3.5 mg/g and dexamethasone 1 mg/g) into the affected eye(s) every 4-6 hours; in severe cases, every 1-2 hours initially and tapered. For otic use: 3-4 drops into the affected ear(s) 3-4 times daily. Topical: apply thin layer to affected area 1-3 times daily.
| Dosage form | SOLUTION/DROPS |
| Renal impairment | No dose adjustment required for topical/ophthalmic/otic use; systemic absorption is negligible. For rare systemic use: avoid if eGFR <30 mL/min/1.73 m² due to cumulative ototoxicity and nephrotoxicity of neomycin. |
| Liver impairment | No dose adjustment required for topical/ophthalmic/otic use. For systemic use: caution in severe hepatic impairment (Child-Pugh C) due to potential corticosteroid toxicity; use lowest effective dose and shortest duration. |
| Pediatric use | Safety and efficacy in children have not been established for ophthalmic/otic use; use only if clearly needed. For topical: apply thin layer 1-3 times daily; avoid prolonged use. Weight-based dosing not applicable for topical/ophthalmic/otic routes. |
| Geriatric use | No specific dose adjustment required; use with caution due to increased risk of ocular adverse effects (e.g., increased intraocular pressure, cataract formation) with prolonged dexamethasone use. Monitor intraocular pressure and for secondary infections. |
| 1st trimester | Consult provider |
| 2nd trimester | Consult provider |
| 3rd trimester | Consult provider |
Clinical note
Other nephrotoxic or ototoxic drugs increase risk of toxicity Can cause ototoxicity and nephrotoxicity with systemic use.
| FDA category | Animal |
| Breastfeeding | Neomycin: Poorly absorbed orally; systemic levels from topical use are negligible. Dexamethasone: Excreted in breast milk; M/P ratio unknown. Approved otic/ophthalmic doses result in very low milk concentrations. Risk to nursing infant is minimal with topical/otic use. |
| Teratogenic Risk | Neomycin: Oral neomycin is poorly absorbed; topical/otic use results in negligible systemic absorption, thus minimal teratogenic risk. Dexamethasone: Corticosteroids are associated with a small increased risk of oral clefts when used in the first trimester (odds ratio ~1.3-1.6); second/third trimester use may cause fetal adrenal suppression, low birth weight, and preterm delivery. Overall risk is low with otic/ophthalmic doses. |
■ FDA Black Box Warning
Neomycin may cause neurotoxicity, ototoxicity, and nephrotoxicity, especially in patients with renal impairment or prolonged use. Avoid use in patients with myasthenia gravis or neuromuscular disorders.
| Common Effects | topical infections |
| Serious Effects |
Hypersensitivity to neomycin, dexamethasone, or any component; epithelial herpes simplex keratitis; vaccinia, varicella, or other viral infections; mycobacterial or fungal infections of the eye; untreated purulent infections.
| Precautions | Prolonged use may lead to secondary infections (e.g., fungal), elevated intraocular pressure, cataract formation, delayed wound healing. Use caution in patients with glaucoma, diabetes, or tuberculosis. Discontinue if hypersensitivity, ototoxicity, or nephrotoxicity occurs. |
Loading safety data…
| Fetal Monitoring | No specific monitoring required for topical/otic use. With prolonged systemic corticosteroid use (high-dose, chronic), monitor for maternal hyperglycemia, fetal growth restriction via serial ultrasound, and neonatal adrenal insufficiency at birth. |
| Fertility Effects | No known effects on fertility from topical/otic neomycin or dexamethasone. Systemic high-dose corticosteroids may suppress gonadotropins and impair ovulation/ menstrual cyclicity. |